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Drugs targeting the viral enzyme integrase have been in use for several years as part of the treatment
regimen for patients with human immunodeficiency virus type 1 (HIV-1), and similar classes of compounds
have been shown to inhibit human T-cell leukemia virus type 1 (HTLV-1) integration in vitro. The current study
shows that the clinically approved HIV-1 integrase inhibitor, raltegravir, as well as the more recent diketo acid
derivative, MK-2048, are active inhibitors of HTLV-1 infection in vitro. These agents were effective in inhibiting
cell-free and cell-to-cell transmission of HTLV-1 in lymphoid and nonlymphoid cells. The drugs also inhibited
HTLV-1 immortalization of human peripheral blood mononuclear cells. A novel adaptation of the Alu assay for
viral integration was used to show that the drugs inhibit viral integration without affecting reverse transcrip-
tion. These data support the administration of raltegravir and other integrase inhibitors as treatments for
patients with HTLV-1-associated diseases.
The retrovirus human T-cell leukemia virus type 1 (HTLV-1) is
the etiologic agent of the malignancy adult T cell leukemia (ATL)
and the neurological disorder HTLV-1-associated myelopathy/
tropical spastic paraparesis (HAM/TSP). HTLV-1 is endemic in
Southern Japan, the Caribbean, and parts of Africa. There are
more than 20 million infected individuals worldwide. The rates of
seroprevalence range from 37% in some Japanese communities
to 0.01% in parts of Europe (reviewed in reference 17). Al-
though relatively rare in North America, HTLV-1 is commonly
found among intravenous drug users (9).
Hallmarks of the retroviral life cycle are the reverse tran-
scription of the viral RNA genome to produce a DNA copy
that is then inserted into the host cell DNA, a process catalyzed
by the virus-encoded enzyme integrase. The integrated viral
DNA is referred to as the provirus. HTLV-1 primarily targets
CD4 lymphocytes and, to a lesser extent, CD8 T lympho-
cytes in vivo (15). Upon infection, the virus enters a long
clinical latency stage ranging from 10 to 50 years, and in-
fected individuals become asymptomatic, seropositive carriers.
After the latent stage, ca. 5% of infected individuals develop
ATL or HAM. The majority of ATL patients die within 2 years
of presentation with symptoms.
Although host cell factors are believed to contribute to in-
tegration site preference, integrase is the principal viral deter-
minant of integration target site specificity (reviewed in refer-
ence 3). Chimeric HIV virus carrying murine leukemia virus
(MLV) integrase instead of HIV integrase exhibits target site
specificity more consistent with that of MLV (11). Integrase
catalyzes the insertion of viral cDNA in three stages: complex
assembly, 3 processing, and strand transfer (5, 24). In the
complex assembly stage, integrase forms a stable complex with
specific viral long terminal repeat (LTR) sequences, after
which the 3 ends of the viral DNA are trimmed, removing a
dinucleotide and exposing reactive 3-OH groups. The 3-OH
groups at the viral DNA ends then covalently attack phos-
phodiester bonds in the host DNA, cleaving the DNA, and
covalently linking the 3 viral cDNA ends to the host cell DNA
in the final stage known as the strand transfer reaction.
A class of compounds known as diketo acids and which are
active inhibitors of the strand transfer reaction of HIV-1 inte-
grase was approved for use in patients in 2007 (7). Recent
structural data indicate that strand transfer inhibitors work by
creating stable intermolecular interactions with active-site res-
idues of the integrase protein. The binding of the drug results
in the displacement of viral DNA from the integrase active site
and the prevention of strand transfer (6; reviewed in reference
16). A derivative of these compounds, the pyrimidine carbox-
amide MK-0518 (raltegravir), has been approved for use in
patients with human immunodeficiency virus (HIV) and has
demonstrated fewer drug-related clinical adverse events than
currently used antiretroviral therapies (13).
Several antiviral agents are currently used in the treatment
of ATL, including zidovudine and interferon alpha 2a, but
these drugs have proven to be only partially successful. In a
clinical trial undertaken to assess the efficacy of chemotherapy,
followed by antiretroviral therapy (interferon alpha, zido-
vudine, and lamivudine) in patients with acute ATL, the ma-
jority of patients had high viral RNA levels at presentation or
during the course of therapy and, while some patient viral
loads remained steady or decreased, several displayed increas-
ing viral RNA levels (19). Along with the changes in viral RNA
levels, some patients had proviral sequences harboring muta-
tions in the reverse transcriptase open reading frame indicating
that the characteristic error-prone retrovirus replication pro-
cess may have been reactivated (19). Examination of viral
integration sites in blood samples from these patients revealed
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the presence of new integration sites with accompanying dis-
ease progression.
Given the structural and functional similarities between the
HIV-1 and HTLV-1 integrases, some inhibitors that are active
against HIV-1 integrase may also be active against HTLV-1
integrase. Rabaaoui et al. (18) were the first to show that two
classes of compounds known to act against HIV-1 integrase—
diketo acids (DKA) and styrylquinolines—are also active
against HTLV-1 integrase in vitro and ex vivo. We show here
that the DKA-based compounds raltegravir and a more re-
cently synthesized inhibitor, MK-2048, display potent antiviral
activity against HTLV-1 in vitro. We used cell culture models
of both cell-free and cell-to-cell transmission of HTLV-1 in a
variety of cell types, including the lymphoid cell line Jurkat and
isolated human peripheral blood mononuclear cells (PBMC)
to demonstrate that raltegravir and MK-2048 actively prevent
HTLV-1 viral integration in vitro, suggesting that integrase
inhibitors may be a valuable addition to treatment regimens for
patients with ATL.
MATERIALS AND METHODS
Cell lines and media. Human PBMC were isolated from normal HTLV-1-
negative donors, stimulated with 10 g of phytohemagglutinin (PHA)/ml and 50
U of interleukin-2 (IL-2)/ml for 4 days, and maintained in complete RPMI with
50 U of IL-2/ml. Jurkat and MT2 cell lines were maintained in RPMI supple-
mented with 10% FetalClone III, 2 mM L-glutamine, and 100 g of penicillin and
streptomycin/ml. B5Luc cells are B5 cells (derived from the DBS-FRhL rhesus
monkey lung fibroblast line) with a stably integrated luciferase reporter gene
under the control of a Tax-inducible LTR promoter. B5Luc and 293T cells were
maintained in Dulbecco modified Eagle medium (DMEM) supplemented with
10% FetalClone III, 2 mM L-glutamine, 100 g of penicillin and streptomycin/ml,
and 1 mM sodium pyruvate.
Virus stock generation. 293T cells were seeded at 4  106 per 10-cm plate and
subsequently transfected with 3 g of packaging plasmid, 3 g of GFP-Luc
plasmid (both gifts from D. Derse, National Cancer Institute [4]), and 0.5 g of
vesicular stomatitis virus G protein (VSV-G) encoding plasmid using TransIT
transfection reagent (Mirus) according to established protocols. The transfection
mixture was replaced with 8 ml of complete DMEM 4 h after transfection, and
virus-containing supernatants were collected 72 h later. Virus stocks were cleared
of transfected cells by low-speed centrifugation, followed by filtration through
0.45-m-pore-size filters.
Cell-free virus infections using recombinant virus vectors. 293T cells were
seeded at 2.5  105 per well in 12-well plates, followed by incubation in the
presence of various concentrations of inhibitors for 4 h. Inhibitors were dissolved
in dimethyl sulfoxide. All assays were performed in triplicate. The medium was
removed and replaced with 350 l of virus-containing supernatant, and the cells
were incubated at 37°C overnight. Complete medium was added to the required
final inhibitor concentrations, and the cells were incubated at 37°C for an addi-
tional 72 h; they were then lysed, and Promega luciferase assays were performed.
Cell-to-cell infections. MT2 cells (106 cells lethally irradiated by exposure to 1
Gy) were added to 107 Jurkat cells that had been incubated for 4 h in medium
containing various concentrations of raltegravir or MK-2048. After an initial 48 h
of incubation, 75% of the cells from each flask were removed and replaced with
fresh medium. The cells were passaged twice more, each time removing 75% of
the total cell population. At 10 days postinfection, the remaining cells were
counted by trypan blue staining, and DNA was extracted from 5  106 cells from
each flask for analysis by Alu assay for viral integration. To determine whether
contaminating MT2 cells were contributing to the measured number of integra-
tions, irradiated MT2 cells and Jurkat cells were counted, maintained in separate
flasks, passaged separately as described, mixed on day 10, and immediately
counted and lysed for DNA extraction. We called this flask the t  0 time point,
representing an infection time of 0 h.
B5 Luc cells were seeded at 5  105 cells per well in six-well plates and
incubated overnight in the presence of various concentrations of inhibitor. Irra-
diated MT2 cells (5  105 per well) were added in medium containing the
corresponding drug concentrations and maintained for 6 days by replacement of
half the total volume of medium every 48 h. On day 6, the cells were lysed, and
Promega luciferase assays were performed.
Alu real-time assay for viral integration. A standard curve was prepared from
MT2 cell DNA extracted by using a DNeasy Blood & Tissue Kit (Qiagen)
according to the manufacturer’s instructions and sequentially diluted in water to
stocks containing DNA from 30, 300, and 3,000 MT2 cells per 4-l volume. DNA
from Jurkat cells infected by cell-to-cell infections, as outlined above, was ex-
tracted by the same method, eluted in 100 l of Tris-EDTA (TE) buffer, and
diluted in water to the equivalent of DNA from 20,000 cells per 4-l volume.
DNA samples were subjected to two rounds of PCR, in which the first round
amplified the DNA sequence between the HTLV-1 LTR and the nearest chro-
mosomal Alu element and the second nested PCR amplified the first round PCR
products. The assay was done with an HTLV-1 LTR sequence-specific probe.
First round PCR was performed using the forward primer HTLV-RTF (ATGC
CACGTAAGCGAAACTGCGCCGTCTAGGTAAGTTTAAAGCTCAGG; the
5 linker sequence is underlined and followed by sequence complementary to
HTLV-1 LTR) and the Alu primers (TCCCAGCTACTGGGGAGGCTGAGG
and GCCTCCCAAAGTGCTGGGATTACAG). Primer concentrations for the
first reaction were 375 nM for each of the primers in a total reaction volume of
20 l. An initial 95°C denaturation step of 8 min was followed by 12 cycles of
amplification (95°C for 30 s, 58°C for 30 s, and 72°C for 2 min). The second-
round real-time PCR was performed with the primers L-T (ATGCCACGTAA
GCGAAACTGC) specific to the linker sequence and RTR2 (GAAACAAAG
ACGTAGAGTTGAGCAAGC) complementary to the HTLV-1 LTR and the
HTLV-1 LTR-specific probe (56-FAM-AGCCTACCTAGACTCAGCCGGCT
CTCCACGCTTTG-3IABlkFQ) with iQ Supermix reagent (Bio-Rad) according
to the manufacturer’s instructions. All samples were performed in triplicate with
primer concentrations of 350 nM for the probe and 400 nM for L-T and RTR2
in a final volume of 50 l. This reaction was performed with an initial 95°C
denaturation step for 5 min, followed by 40 cycles of amplification (95°C for 30 s,
60°C for 1 min, and 72°C for 30 s). Experimental samples were compared to the
MT2 DNA-generated standard curve using a value of three copies of integrated
HTLV-1 viral DNA per MT2 cell (1). Reactions were also performed in the
absence of Alu primers, and these values were subtracted from those obtained in
the presence of the primers in order to account for false-positive signals due to
linear amplification of products in the first reaction.
Total DNA assay. A 2.5-l portion of infected cell DNA prepared as described
above was subjected to one round of PCR amplifying a sequence in the tax region
of the genome. The forward and reverse primers were HTLV-1Fwd (AAGAC
TGTTTGCCCACCACC) and HTLV-1Rev (TTGCCAGGCTGTTAGCGTG),
respectively. Reactions were performed in triplicate with iQ SYBR green Su-
permix 2 mix for real-time PCR applications (Bio-Rad) in 25-l volume reac-
tions with final primer concentrations of 0.25 M each. After an initial 10-min
denaturation of 95°C, 40 rounds of amplification were performed (95°C for 15 s,
60°C for 30 s, and 60°C for 12 s). The samples were then held at 72°C for 10 s
before melting-curve analysis was performed according to established protocols.
For a total DNA assay at 24 h postinfection, 3  106 293T cells were plated in
T25 flasks, followed by incubation in the presence or absence of integrase or
reverse transcriptase inhibitor for 4 h. Then, 106 irradiated MT2 cells were
added per flask, and infections were allowed to occur for 24 h at 37°C. DNA
was extracted by using a Qiagen DNeasy Blood & Tissue Kit according to the
manufacturer’s instructions and eluted in 100 l of TE buffer. Total DNA
assays were performed as described above with 2.5 l of a 1:10 dilution of
infected DNA in water and compared to a standard curve generated by
performing the assay on dilutions of DNA extracted from MT2 cells. A value
of three copies of viral DNA per MT2 cell was used to compare the total viral
DNA across the various samples (1).
Determining linearity of MT2 standard curve. Jurkat cells were infected for 10
days by cell-cell infection with irradiated MT2 cells in the absence of inhibitors
as described above. DNA from 2  104, 1  104, 4  103, and 2  102 infected
cells were diluted, where necessary, in carrier DNA (uninfected Jurkat DNA
diluted in water) so that the total DNA contributed from the mixture of infected
and uninfected DNA would be equivalent to DNA from 2  104 cells. Alu assays
were performed on each sample as described above.
PBMC immortalization assay. PBMC (5 106) were maintained in T25 flasks
in 10 ml of complete RPMI containing 50 U of IL-2/ml (no PHA) and raltegravir,
in specified concentrations, and then incubated at 37°C overnight. The following
day, 106 irradiated MT2 cells were added to the appropriate flasks. The cells
were counted at specified time points by trypan blue staining.
Cell viability assays. MTT assays were performed according to established
protocols. 293T cells (2  105/well) were plated in a 12-well plate and exposed
to various concentrations of inhibitor or staurosporine (positive control for cell
death) for 72 h at 37°C. MTT assay reagent was added, and cells were incubated
at 37°C overnight. The cells were lysed in isopropanol, and the optical density
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values at 560 nm were measured. CellTiter-Blue (Promega) cell viability assays
were performed according to the manufacturer’s protocols.
p19 antigen enzyme-linked immunosorbent assay (ELISA). Reactions were
performed according to standard protocols. A 450-l portion of each superna-
tant was collected and lysed with 50 l of lysing buffer. Then, 200-l portions of
lysed supernatants were placed in duplicate wells of a 96-well plate, and optical
densities of each well were read at 450 nm and compared to that of an HTLV-1
antigen standard by using a Tecan Spectrafluor Plus microplate reader.
Statistical analysis. The results of all assays were compared by using a two-
tailed t test. All statistical analyses compared inhibitor-treated cells to cells that
were maintained in medium without drug.
RESULTS
Determining the efficacy of integrase inhibitors against
HTLV-1 infection via cell-free infection with recombinant vi-
rus vectors. We first utilized a cell-free infection assay (4) to
gauge the effectiveness of a panel of drugs against HTLV-1
infectivity. Infectious virus was generated from transfected
cells as detailed above and used to infect 293T cells exposed to
various concentrations of drugs. We verified that the virus
produced by this method was inhibited by zidovudine (AZT)
with a 50% effective concentration (EC50) of 50 nM, in accor-
dance with previously published values (4; data not shown).
The experiments were repeated with various concentrations of
integrase inhibitors provided by Merck & Co., Inc., including
L-870,810, raltegravir (Fig. 1A), and MK-2048 (Fig. 1B).
L-870,810 and raltegravir displayed EC50s near the 50 nM
range, and treatment with MK-2048 resulted in an EC50 of 1
nM (Fig. 2 and data not shown). Since raltegravir is already
approved for clinical use, we decided to focus the rest of the
experiments on this compound, and the more recently devel-
oped integrase inhibitor MK-2048. Both compounds showed
little or no toxicity against 293T cells, indicating that decreased
levels of infection observed in the presence of the inhibitors
are not attributable to inhibitor toxicity (Fig. 2C).
MK-2048 and raltegravir are effective inhibitors of HTLV-1
infection via cell-to-cell transmission. HTLV-1 infection is
primarily achieved through cell-to-cell transmission of virus
particles (8). We next tested whether this mode of infection
was also subject to inhibition by MK-2048 and raltegravir using
B5Luc cells, which are B5 cells (primate kidney fibroblasts)
containing a stably integrated luciferase gene under the control
of an HTLV-1 LTR promoter (20). Infection of this cell line by
HTLV-1 activates the Tax-inducible promoter, resulting in lu-
ciferase expression. Infection of B5Luc cells by lethally irradi-
ated MT2 cells, an HTLV-1 transformed lymphoid cell line,
was significantly impaired in the presence of raltegravir and
MK-2048 at concentrations similar to those observed in the
cell-free infection assay (Fig. 3).
Raltegravir and MK-2048 inhibit HTLV-1 integration in
target cells. We examined HTLV-1 integration by adapting the
Alu assay for viral integration (2) to our HTLV-1 cell-to-cell
infection model. Briefly, the assay involves two PCR steps
whereby the first step amplifies the DNA sequence between
the HTLV-1 LTR and the nearest chromosomal Alu element,
and the second nested PCR amplifies the first-round PCR
products. To our knowledge, this is the first time the Alu assay
FIG. 1. Chemical structures of the integrase inhibitors MK-0518
(A), also known as raltegravir and Isentress, and MK-2048 (B).
FIG. 2. Raltegravir and MK-2048 significantly inhibit cell-free in-
fection by recombinant HTLV-1 in vitro and are not toxic to target
cells. The cell-free infection of 293T cells with luciferase-encoding
recombinant HTLV-1 in the presence of increasing concentrations of
MK-2048 (A) and raltegravir (B) was assessed. (C) MTT assays for cell
viability were performed in the presence of each of the two drugs and
of the apoptosis-inducing drug staurosporine. Each data point repre-
sents the mean of three individual values (, P  0.05; , P  0.01
[error bars indicate the standard deviation]).
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for viral integration has been successfully adapted to measure
HTLV-1 genomic integration. Total viral DNA was quantified
by real-time PCR using primers to the viral tax gene. We tested
whether the lymphoid cell line, Jurkat, was affected by the
inhibitors in the context of cell-cell viral transmission. As ex-
pected, both raltegravir and MK-2048 were effective in reduc-
ing the number of integrated viral copies in the target cell line
at concentrations within the range identified in the previous
cell-free infection, and the B5Luc infection assays (Fig. 4A and
B). No integrations were detectable in a sample of MT2 cells
after irradiation and cultivation alone for 10 days (data not
shown). Raltegravir displayed no toxicity against Jurkat cells,
indicating that decreased levels of infection observed in the
presence of the inhibitor are not attributable to inhibitor tox-
icity (Fig. 4C). The standard curve from MT2 cells was reliable
in predicting integrations on a linear scale over a 10-fold dilu-
tion of infected DNA in carrier DNA (Fig. 4D).
Raltegravir prevents immortalization of human PBMC in a
dose-dependent manner. MT2 cells produce infectious virus
FIG. 3. Raltegravir and MK-2048 significantly inhibit HTLV-1 cell-
cell infection of B5 Luc cells. B5Luc cells (fetal rhesus lung cell line
clone B5 containing a stably integrated luciferase gene under the
control of a Tax-inducible LTR) were coincubated with lethally irra-
diated MT2 cells in the presence or absence of the indicated concen-
trations of MK-2048 and raltegravir. Each bar represents the mean of
three values (, P  0.05; , P  0.01 [error bars indicate standard
deviation]).
FIG. 4. Raltegravir and MK-2048 reduce the number of viral integration events and total viral DNA levels per cell in cell-cell infections of
Jurkat cells and is not toxic to the cells. (A) Jurkat cells were infected by coincubation with lethally irradiated MT2 cells for 48 h and passaged
three times over a period of 10 days in the presence or absence of various concentrations of raltegravir and MK-2048. The number of copies of
integrated DNA per cell was measured by Alu assay (A), while the total DNA per cell was measured by real-time PCR analysis using primers to
tax (B). Each bar represents the mean of three values. (C) Jurkat cells were either untreated or incubated in medium containing 500 nM or 5 M
raltegravir and then passaged for 9 days. A 100-l portion of a 1:5 dilution of each cell category was analyzed by using the CellTiter-Blue cell
viability assay (Promega). The data represent the means of triplicate readings with background (medium only) subtracted. (D) Jurkat cells infected
by cell-cell contact with irradiated MT2 cells were diluted in carrier DNA and subjected to analysis by Alu assay for viral integration. Each data
point is the mean of three values (, P  0.05; , P  0.01 [error bars indicate the standard deviation]).
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capable of immortalizing uninfected PBMC (21). We tested
whether raltegravir would lower the propensity of the PBMC
to be immortalized by virus from MT2 cells by coculturing
irradiated MT2 cells with PBMC in the presence of various
concentrations of raltegravir. Uninfected PBMC proliferated
for 4 weeks, after which they steadily decreased in number and
were all dead after 9 weeks in culture, whereas the irradiated
MT2 cells alone did not proliferate (data not shown). In the
absence of inhibitor, PBMC cultured in the presence of MT2
cells proliferated indefinitely (89 days), and the number of
immortalized cells decreased with increasing concentrations of
raltegravir (Fig. 5A). HTLV-1 p19 antigen ELISA performed
on viral supernatants removed at day 41 after culture indicated
that there was significantly less virus production in raltegravir-
treated cells compared to the untreated control (Fig. 5B). As
expected, cells cultured for 89 days in the presence of inhibitor
displayed a significant decrease in the number of copies of
integrated DNA and total DNA relative to the untreated con-
trol (Fig. 5C and D).
Antiviral effects of raltegravir and MK-2048 are exhibited at
the stage of integration in HTLV-1 cell-cell transmission. The
class of integrase inhibitors described here has been shown to
act at the stage of strand transfer in HIV-1 viral integration (7)
and in in vitro studies of HTLV-1 integration (18). We mea-
sured the consequence of this block on the viral replication
cycle by measuring the number of integration events in a cell
population. However, any antiviral agent that acts at or before
the stage of strand transfer would have the same effect on the
number of integrated copies of virus. Treatment of target cells
with the nucleoside analog reverse transcriptase inhibitor AZT
resulted in a similar decrease in integrated viral DNA in both
293T and Jurkat cells (data not shown). However, because
multiple rounds of replication were necessary for these assays,
the decrease in integrated DNA was accompanied by a de-
crease in total viral DNA. If the integrase inhibitors are acting
to prevent integration and not at an earlier stage, then we
would expect to observe either an increase or no change in
total viral DNA at early stages of infection. Therefore, we
performed total DNA assays on 293T cells infected with le-
thally irradiated MT2 cells for 24 h in the presence of MK-2048
and raltegravir, as well as with AZT as a positive control for
inhibition of reverse transcription. As expected, total viral
DNA levels were significantly diminished by AZT, whereas
there was an increase in total viral DNA in raltegravir-treated
cells and no significant change in cells treated with MK-2048,
indicating that the compounds are effective inhibitors of
HTLV-1 viral integration (Fig. 6).
DISCUSSION
Our data demonstrate that the clinically approved HIV-1
integrase inhibitor raltegravir and the newer DKA-derived
drug MK-2048 prevent integration of HTLV-1 in vitro for both
cell-free and the more physiologically relevant cell-to-cell
modes of infection. We utilized a novel application of the Alu
assay for viral integration to measure HTLV-1 integration
FIG. 5. Raltegravir blocks infection of PBMC by HTLV-1 cell-to-cell transmission from irradiated MT2 cells. PBMC were extracted from whole
blood and coincubated with irradiated MT2 cells for 90 days. (A) Cell viability was measured by trypan blue stain resistance at the indicated time
points approximately 1 week apart. Each data point is the mean of three cell counts. (B) Viral production was measured from supernatants
collected at day 41 after culture and quantified by p19 antigen ELISA (Zeptometrix). Each bar represents the mean of two measurements. The
number of integrated proviral copies per cell was measured by Alu assay (C), and the total DNA measured by real-time PCR analysis (D) (, P 
0.05; , P  0.01 [error bars indicate standard deviation]). The reported values are the means of three measurements; R-0, R-100, R-250, and
R-500 represent infected PBMC cultured in 0, 100, 250, and 500 nM raltegravir, respectively.
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events in infected cell populations. The effects of DKA deriv-
atives on HTLV-1 viral integration have not been widely stud-
ied. Rabaaoui et al. (18) showed that two DKA inhibitors,
L-731,988 and L-839,616, prevented HTLV-1 strand transfer
with 50% inhibitory concentrations between 50 and 70 nM.
These values were obtained from fluorescent PCR quantifica-
tion of the transfer of synthetic strands of DNA to target
sequences in the presence of purified recombinant HTLV-1
integrase in cell-free reactions. In contrast, we used in vitro cell
culture models to calculate significantly lower EC50s of 35 and
1 nM for raltegravir and MK-2048, respectively. We also dem-
onstrated that the integrase inhibitor-mediated reduction of
the spread of virus by cell-cell transmission, the primary route
of HTLV-1 viral propagation, occurred with similar EC50s for
these drugs. As with HIV-1 infection, MK-2048 demonstrated
significantly improved potency over the original drug, raltegra-
vir, in the context of HTLV-1 infection (23).
One of the problems associated with studying HTLV-1 in-
fection in vitro is the relative difficulty of infecting target cells.
Real-time methods to measure total viral DNA are hampered
by the presence of contaminating plasmid DNA in infections
utilizing cells transfected with the HTLV-1 molecular clone.
To circumvent this, we used lethally irradiated cells from the
chronically infected HTLV-1 cell line MT2 and, over a period
of 10 days, passaged the cells to remove as much background
contamination as possible. Over the 10 days, the integrase
inhibitors blocked new integrations, reducing the reservoir of
integrated virus available for transcription, thus blocking virus
spread and decreasing total viral DNA levels. This decrease in
total viral DNA in the presence of the integrase inhibitors
rendered the antiviral activity of the compounds indistinguish-
able from the reverse transcriptase inhibitor, AZT, as demon-
strated by the Alu assay. Since Jurkat cells did not display high
levels of infection above background levels up to 36 h postin-
fection (data not shown), we used 293T cells to show that
whereas AZT caused a highly significant decrease in total viral
DNA levels 24 h postinfection, the integrase inhibitors either
increased or did not change total viral DNA, indicating that
the antiviral effect of the inhibitors is exhibited after reverse
transcription.
HIV-1 replicates more efficiently at early stages in infection
than HTLV-1 due to its selective targeting to active genes (10,
22). HTLV-1 integration targeted to actively transcribed
genomic regions has been associated with more rapid and
aggressive disease progression in patients with HAM/TSP (14).
ATL patients enrolled in a recent clinical trial displayed high
viral RNA levels at presentation or during the course of ther-
apy. Some patients displayed increasing viral RNA levels and
proviral sequences harboring mutations in the reverse trans-
criptase open reading frame, indicating possible viral reactiva-
tion (19). A combination of HTLV-1 Tax expression and T cell
receptor stimulation have been shown to coactivate viral and
cellular gene expression, thereby promoting latent HTLV-1
production (12). The cause-and-effect relationship—whether
viral expression is simply a consequence of progression and
perhaps a result of lymphocyte activation or whether virus
expression and mutation are causing new and more conse-
quential integrations, thus leading to progression—remains
unknown.
ATL is a disease with a poor prognosis; the majority of ATL
patients die within 2 years of presentation with symptoms and
treatment options are currently very limited. The combination
of chemotherapy with integrase inhibitors may be a viable
treatment option for these patients.
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